Immunohematology最新文献_第3页

A patient with anti-f in India identified by extensive immunohematologic workup. 通过大量免疫血液学检查发现的一名印度抗 F 患者。

Immunohematology Pub Date : 2024-06-24 eCollection Date: 2024-06-01 DOI: 10.2478/immunohematology-2024-008

Sunil Golia, Samruddhi Pawar, Aseem K Tiwari, Geet Aggarwal, Neetu Singh, Shubham Gupta

引用次数: 0

How anti-c in a D- patient prompted lifesaving work between a transfusion service and a blood center reference laboratory. 一名 D 级病人的抗生素如何促使输血服务机构和血液中心参考实验室开展挽救生命的工作。

Immunohematology Pub Date : 2024-06-24 eCollection Date: 2024-06-01 DOI: 10.2478/immunohematology-2024-011

Gavin Patch, Joan Maurer, Arun Sendilnathan, Christine Leak, Elizabeth Nartowicz, Victoria Kavitsky, Dexter Facey, Sandra T Nance, Margaret A Keller

引用次数: 0

When and why is red blood cell genotyping applicable in transfusion medicine: a systematic review of the literature. 红细胞基因分型何时以及为何适用于输血医学：文献系统综述。

Immunohematology Pub Date : 2024-06-24 eCollection Date: 2024-06-01 DOI: 10.2478/immunohematology-2024-009

Thompson J Akinbolaji

{"title":"When and why is red blood cell genotyping applicable in transfusion medicine: a systematic review of the literature.","authors":"Thompson J Akinbolaji","doi":"10.2478/immunohematology-2024-009","DOIUrl":"10.2478/immunohematology-2024-009","url":null,"abstract":"This review aims to provide a better understanding of when and why red blood cell (RBC) genotyping is applicable in transfusion medicine. Articles published within the last 8 years in peer-reviewed journals were reviewed in a systematic manner. RBC genotyping has many applications in transfusion medicine including predicting a patient's antigen profile when serologic methods cannot be used, such as in a recently transfused patient, in the presence of autoantibody, or when serologic reagents are not available. RBC genotyping is used in prenatal care to determine zygosity and guide the administration of Rh immune globulin in pregnant women to prevent hemolytic disease of the fetus and newborn. In donor testing, RBC genotyping is used for resolving ABO/D discrepancies for better donor retention or for identifying donors negative for high-prevalence antigens to increase blood availability and compatibility for patients requiring rare blood. RBC genotyping is helpful to immunohematology reference laboratory staff performing complex antibody workups and is recommended for determining the antigen profiles of patients and prospective donors for accurate matching for C, E, and K in multiply transfused patients. Such testing is also used to determine patients or donors with variant alleles in the Rh blood group system. Information from this testing aides in complex antibody identification as well as sourcing rare allele-matched RBC units. While RBC genotyping is useful in transfusion medicine, there are limitations to its implementation in transfusion services, including test availability, turn-around time, and cost.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"40 2","pages":"58-64"},"PeriodicalIF":0.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of transcription factors KLF1 and GATA1 on red blood cell antigen expression: a review. 转录因子 KLF1 和 GATA1 对红细胞抗原表达的影响：综述。

Immunohematology Pub Date : 2024-05-13 eCollection Date: 2024-04-01 DOI: 10.2478/immunohematology-2024-002

Genghis H Lopez, Mia E Sarri, Robert L Flower, Catherine A Hyland

{"title":"Impact of transcription factors KLF1 and GATA1 on red blood cell antigen expression: a review.","authors":"Genghis H Lopez, Mia E Sarri, Robert L Flower, Catherine A Hyland","doi":"10.2478/immunohematology-2024-002","DOIUrl":"10.2478/immunohematology-2024-002","url":null,"abstract":"KLF transcription factor 1 (KLF1) and GATA binding protein 1 (GATA1) are transcription factors (TFs) that initiate and regulate transcription of the genes involved in erythropoiesis. These TFs possess DNA-binding domains that recognize specific nucleotide sequences in genes, to which they bind and regulate transcription. Variants in the genes that encode either KLF1 or GATA1 can result in a range of hematologic phenotypes-from benign to severe forms of thrombocytopenia and anemia; they can also weaken the expression of blood group antigens. The Lutheran (LU) blood group system is susceptible to TF gene variations, particularly KLF1 variants. Individuals heterozygous for KLF1 gene variants show reduced Lutheran antigens on red blood cells that are not usually detected by routine hemagglutination methods. This reduced antigen expression is referred to as the In(Lu) phenotype. For accurate blood typing, it is important to distinguish between the In(Lu) phenotype, which has very weak antigen expression, and the true Lunull phenotype, which has no antigen expression. The International Society of Blood Transfusion blood group allele database registers KLF1 and GATA1 variants associated with modified Lutheran expression. Here, we review KLF1 and recent novel gene variants defined through investigating blood group phenotype and genotype discrepancies or, for one report, investigating cases with unexplained chronic anemia. In addition, we include a review of the GATA1 TF, including a case report describing the second GATA1 variant associated with a serologic Lu(a-b-) phenotype. Finally, we review both past and recent reports on variations in the DNA sequence motifs on the blood group genes that disrupt the binding of the GATA1 TF and either remove or reduce erythroid antigen expression. This review highlights the diversity and complexity of the transcription process itself and the need to consider these factors as an added component for accurate blood group phenotyping.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"40 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antenatal RHD screening to guide antenatal anti-D immunoprophylaxis in non-immunized D- pregnant women. 产前 RHD 筛查，为未免疫 D 型血孕妇的产前抗 D 型血免疫预防提供指导。

Immunohematology Pub Date : 2024-05-13 eCollection Date: 2024-04-01 DOI: 10.2478/immunohematology-2024-004

Frederik B Clausen

{"title":"Antenatal RHD screening to guide antenatal anti-D immunoprophylaxis in non-immunized D- pregnant women.","authors":"Frederik B Clausen","doi":"10.2478/immunohematology-2024-004","DOIUrl":"10.2478/immunohematology-2024-004","url":null,"abstract":"In pregnancy, D- pregnant women may be at risk of becoming immunized against D when carrying a D+ fetus, which may eventually lead to hemolytic disease of the fetus and newborn. Administrating antenatal and postnatal anti-D immunoglobulin prophylaxis decreases the risk of immunization substantially. Noninvasive fetal RHD genotyping, based on testing cell-free DNA extracted from maternal plasma, offers a reliable tool to predict the fetal RhD phenotype during pregnancy. Used as a screening program, antenatal RHD screening can guide the administration of antenatal prophylaxis in non-immunized D- pregnant women so that unnecessary prophylaxis is avoided in those women who carry a D- fetus. In Europe, antenatal RHD screening programs have been running since 2009, demonstrating high test accuracies and program feasibility. In this review, an overview is provided of current state-of-the-art antenatal RHD screening, which includes discussions on the rationale for its implementation, methodology, detection strategies, and test performance. The performance of antenatal RHD screening in a routine setting is characterized by high accuracy, with a high diagnostic sensitivity of ≥99.9 percent. The result of using antenatal RHD screening is that 97-99 percent of the women who carry a D- fetus avoid unnecessary prophylaxis. As such, this activity contributes to avoiding unnecessary treatment and saves valuable anti-D immunoglobulin, which has a shortage worldwide. The main challenges for a reliable noninvasive fetal RHD genotyping assay are low cell-free DNA levels, the genetics of the Rh blood group system, and choosing an appropriate detection strategy for an admixed population. In many parts of the world, however, the main challenge is to improve the basic care for D- pregnant women.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"40 1","pages":"15-27"},"PeriodicalIF":0.0,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update to Kidd blood group system. 更新基德血型系统。

Immunohematology Pub Date : 2024-05-13 eCollection Date: 2024-04-01 DOI: 10.2478/immunohematology-2024-005

Janis R Hamilton

引用次数: 0

Meeting the transfusion needs of a patient with anti-En^a requires an international effort. 满足抗 Ena 患者的输血需求需要国际社会的共同努力。

Immunohematology Pub Date : 2024-05-13 eCollection Date: 2024-04-01 DOI: 10.2478/immunohematology-2024-003

Stella T Chou, Sandra T Nance, Paul Mansfield, David F Friedman, Margaret A Keller

引用次数: 0

Anti-A and anti-B titers, age, gender, biochemical parameters, and body mass index in Japanese blood donors. 日本献血者的抗 A 和抗 B 滴度、年龄、性别、生化指标和体重指数。

Immunohematology Pub Date : 2023-12-29 eCollection Date: 2023-12-01 DOI: 10.2478/immunohematology-2023-023

M Mikame, N H Tsuno, Y Miura, H Kitazaki, D Uchimura, T Miyagi, T Miyazaki, T Onodera, W Ohashi, T Kameda, R Ohkawa, S Kino, K Muroi

{"title":"Anti-A and anti-B titers, age, gender, biochemical parameters, and body mass index in Japanese blood donors.","authors":"M Mikame, N H Tsuno, Y Miura, H Kitazaki, D Uchimura, T Miyagi, T Miyazaki, T Onodera, W Ohashi, T Kameda, R Ohkawa, S Kino, K Muroi","doi":"10.2478/immunohematology-2023-023","DOIUrl":"10.2478/immunohematology-2023-023","url":null,"abstract":"It has been reported that anti-A and anti-B (ABO antibody) titers decrease with age, but little is known about the association between ABO antibody titers and physiologic/biochemical parameters such as body mass index (BMI), gamma-glutamyl transpeptidase (GGT), and total cholesterol (T-Cho). We investigated the present situation of ABO antibody titers among healthy blood donors in Japan and the physiologic/biochemical factors that may be associated with changes in ABO antibody titers. Plasma from 7450 Japanese blood donors was tested for ABO antibody titers using ABO reverse typing reagents by an automated microplate system; donor samples were classified into low, middle, and high titers according to the agglutination results obtained with diluted plasma samples. Multivariate regression analysis was performed to analyze the association between ABO antibody titers and age, gender, biochemical parameters (alanine transaminase [ALT], GGT, globulin, T-Cho, and glycosylated albumin [GA]), and BMI according to the ABO blood groups. A significant correlation between ABO antibody titers and age/gender, except for gender in anti-A of blood group B donors, was observed. BMI showed significant but negative correlations with anti-A and anti-B (β = -0.085 and -0.062, respectively; p < 0.01) in blood group O donors. In addition, significant but negative correlations between GGT and T-Cho with anti-B of blood group A donors (β = -0.055 and -0.047, respectively; p < 0.05) were observed. Although differences existed among the ABO blood groups, ABO antibody titers seem to be associated with physiologic and biochemical parameters of healthy individuals.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"39 4","pages":"155-165"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of solid-phase red cell adherence and microcolumn agglutination technology using untreated and enzyme-treated red blood cells. 使用未经处理和酶处理的红细胞比较固相红细胞粘附和微柱凝集技术。

Immunohematology Pub Date : 2023-12-29 eCollection Date: 2023-12-01 DOI: 10.2478/immunohematology-2023-024

D R Sanders

{"title":"Comparison of solid-phase red cell adherence and microcolumn agglutination technology using untreated and enzyme-treated red blood cells.","authors":"D R Sanders","doi":"10.2478/immunohematology-2023-024","DOIUrl":"10.2478/immunohematology-2023-024","url":null,"abstract":"Screening for clinically significant antibodies is crucial in transfusion medicine and is a routine part of pre-transfusion testing. The indirect antiglobulin test (IAT) is the most reliable and effective test for detecting clinically significant alloantibodies reacting at the antihuman globulin phase. Two of the main methods used for antibody detection and identification are solid-phase red cell adherence (SPRCA) and microcolumn agglutination technology (CAT), with or without enzyme-treated red blood cells (RBCs). This study was undertaken to detect and identify alloantibodies by performing antibody screen (ABS) and antibody identification (ABID) testing using SPRCA and CAT, with and without ficin-treated RBCs. Residual patient samples collected between 1 December 2020 and 19 May 2021 were saved, de-identified, and frozen at ≤-30°C before testing for alloantibodies. Seventy antibodies were detected in 53 samples among the 203 samples that underwent an ABS. Of those samples, 150 (73.0%) were nonreactive, 47 (23.1%) yielded positive results with both CAT and SPRCA, and six (3.0%) yielded positive ABS results with SPRCA only. Fifty-three samples that underwent ABID by both methods yielded eight samples with antibodies identified by SPRCA only. Additional enhancement of the CAT method by the use of ficin-treated RBCs was required to detect seven of the eight SPRCA-only antibodies; one sample remained nonreactive regardless. SPRCA testing detected clinically significant antibodies without the addition of enzyme-treated RBCs that was necessary in the CAT testing.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"39 4","pages":"166-171"},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

To contributors to the 2023 issues. 致 2023 期刊的撰稿人。

Immunohematology Pub Date : 2023-12-29 eCollection Date: 2023-12-01 DOI: 10.2478/immunohematology-2023-027

引用次数: 0